SCHEMBL543183

SCHEMBL543183

Cc1cc2c([C@@H]3C[C@H]3CNC(=O)c3ccccc3)cccn2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
DRD2 P14416 1/20 0.38
HPGD P15428 4/20 0.38
OPRM1 P35372 3/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
NPC1 O15118 2/20 0.38
PKM P14618 2/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 1/20 0.38
HSP90AA1 P07900 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
OPRK1 P41145 2/20 0.38
RECQL P46063 1/20 0.38
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL543182 1.00 ALDH1A1 (0.38) ALDH1A1DRD2HPGDOPRM1CYP1A2
SCHEMBL2776106 0.90 MTNR1B (0.40) ALDH1A1MTNR1AMTNR1B
SCHEMBL2777245 0.90 MTNR1B (0.40) ALDH1A1MTNR1AMTNR1B
SCHEMBL2779850 0.90 MTNR1B (0.40) ALDH1A1MTNR1AMTNR1B
SCHEMBL543502 0.87 MTNR1B (0.46) MTNR1AMTNR1B
SCHEMBL543749 0.87 MTNR1B (0.46) MTNR1AMTNR1B
SCHEMBL13511851 0.87 MTNR1B (0.46) MTNR1AMTNR1B
SCHEMBL543391 0.87 MTNR1B (0.46) MTNR1AMTNR1B
SCHEMBL544156 0.85 MTNR1B (0.51) MTNR1AMTNR1B
SCHEMBL543583 0.85 MTNR1B (0.51) MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2141150-B1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2013-12-11 EP disclosed
US-8110585-B2 Bicyclic compound and pharmaceutical use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-07 US disclosed
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-05-27 US disclosed
EP-2141150-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-01-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF MTNR1A, MTNR1B, XDH ALDH1A1 1431/4885DRD2 73/4885HPGD 297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.